Lexicon Pharmaceuticals, Inc. (LXRX) Cash Flow Statement
Lexicon Pharmaceuticals, Inc. (LXRX) generated -$65.0M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$65.0M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LXRXLexicon Pharmaceuticals, Inc.Follow LXRX — free
—
Price chart with a free account
- Market cap
- 631.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -87.9 | -94.5 | -91.1 | -75.6 | 184.8 | -175.6 | -185.4 | -148.6 | 113.8 | -143.0 | -87.0 | -88.9 | -161.9 | -178.8 | -67.9 | -65.0 | |
| Capital expenditure | 1.2 | 0.5 | 1.7 | 0.1 | 0.9 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 1.2 | 1.3 | 0.5 | 1.0 | 0.0 | -0.0 | |
| Free cash flow | -89.1 | -95.0 | -92.8 | -75.7 | 183.9 | -175.9 | -185.6 | -148.7 | 113.7 | -143.1 | -88.2 | -90.2 | -162.4 | -179.8 | -67.9 | -65.0 | |
| Share repurchases | 0.1 | 0.3 | 0.9 | 0.9 | 0.4 | 0.6 | 1.7 | 1.0 | 0.9 | 1.0 | 2.7 | 0.9 | 0.8 | 1.7 | — | — | |
| Stock-based compensation | 5.7 | 6.5 | 7.4 | 7.1 | 6.8 | 7.5 | 9.5 | 11.7 | 14.2 | 13.3 | 10.6 | 11.5 | 14.3 | 13.5 | 12.5 | — |
USD millions · SEC XBRL
Lexicon Pharmaceuticals, Inc. — questions
- What is Lexicon Pharmaceuticals, Inc.'s operating cash flow?
- -$65.0M over the twelve months to 2026-06-30.
- How much does Lexicon Pharmaceuticals, Inc. spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is Lexicon Pharmaceuticals, Inc.'s free cash flow?
- -$65.0M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Lexicon Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.